---
title: "Oruka Therapeutics, Inc. (ORKA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ORKA.US.md"
symbol: "ORKA.US"
name: "Oruka Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-04-30T20:03:05.211Z"
locales:
  - [en](https://longbridge.com/en/quote/ORKA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ORKA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ORKA.US.md)
---

# Oruka Therapeutics, Inc. (ORKA.US)

## Company Overview

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [orukatx.com](https://orukatx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -40.55 | 529 | - | - | - |
| PB | 7.29 | 360 | 3.78 | 2.83 | 1.41 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-30T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 85% |
| Overweight | 2 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.50 |
| Highest Target | 49.00 |
| Lowest Target | 15.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ORKA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ORKA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ORKA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ORKA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**